Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance.

CD8+ T cell immunity enhances tumor cell susceptibility to cuproptosis, improving the effectiveness of inducers in overcoming immunotherapy resistance in preclinical models.

• Why it matters: Overcoming resistance to immune checkpoint therapies like anti-PD-L1 remains a major challenge in cancer treatment. Understanding how immune responses influence tumor cell death pathways could reveal new strategies to boost therapy efficacy.
• What they did: The study examined the interaction between CD8+ T cells and tumor cells, demonstrating that interferon gamma (IFN-γ) from T cells upregulates FDX1 via the STAT1-IRF1 pathway, increasing tumor sensitivity to cuproptosis. Combining cuproptosis inducers with anti-PD-L1 therapy was tested across multiple preclinical models.
• The result: This approach significantly amplified tumor cell death and overcame PD-L1 resistance, suggesting that targeting cuproptosis in conjunction with immunotherapy can improve treatment outcomes by leveraging immune-tumor interactions.